RECRUITING

Cancer Therapy Effects on the Heart

Talk to us

Conditions

CardiotoxicityPediatric CancerHeart Failure

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.

Official Title

Cancer Therapy Effects on the Heart: Identification of Early Markers of Cardiac Disease Progression After Cardiotoxic Childhood Cancer Therapy Using Cardiac Magnetic Resonance Imaging

Quick Facts

Study Start:2019-09-30
Study Completion:2029-09-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04262830

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:13 Years to 39 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * English and Spanish speaking male and female subjects, ages 13-39 years old
  2. * Diagnosis of cancer at age \<22 years
  3. * Previously treated with anthracyline therapy for cancer, with diagnosis at least two years prior.
  1. * Patients who have a contraindication to cardiac MRI, including the presence of non-MRI compatible metallic implants.
  2. * Medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac MRI without anesthesia.
  3. * Patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus).
  4. * Patients with orthodontic braces or metallic implants in the thorax or abdomen/lumbar spine, even if MRI-compatible, will be excluded as these may cause artifacts and limit image quality.
  5. * Pregnancy.

Contacts and Locations

Study Contact

Hari Narayan, MD
CONTACT
8589665855
hnarayan@rchsd.org
James Kolar
CONTACT
8585761700
jkolar@rchsd.org

Principal Investigator

Hari Narayan, MD
PRINCIPAL_INVESTIGATOR
University of California San Diego, Rady Children's Hospital

Study Locations (Sites)

Rady Children's Hospital
San Diego, California, 92123
United States

Collaborators and Investigators

Sponsor: Hari Narayan

  • Hari Narayan, MD, PRINCIPAL_INVESTIGATOR, University of California San Diego, Rady Children's Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-09-30
Study Completion Date2029-09-30

Study Record Updates

Study Start Date2019-09-30
Study Completion Date2029-09-30

Terms related to this study

Additional Relevant MeSH Terms

  • Cardiotoxicity
  • Pediatric Cancer
  • Heart Failure